Compass is still being developed and is effectively in beta. Some content and features may be incomplete, change, or not work as expected.

Content is anchored to trusted sources where available, but Compass has not yet been clinically reviewed. It provides general information rather than medical advice.

Feedback helps us identify gaps, errors, usability problems and opportunities to improve Compass over time.

How Compass is developedGive feedback

ALS Untangled reviewed L-carnitine supplements for ALS

Original source

L-CarnitineALSUntangled · 30 July 2020 (opens in a new tab)

ALS Untangled found theoretical reasons and some preclinical evidence supporting carnitines, including L-carnitine and acetyl-L-carnitine. It also identified one clinical trial suggesting that acetyl-L-carnitine might slow disease progression. The group said more clinical trials are needed and did not endorse any of these supplements as a definite treatment for slowing ALS progression.

Why this matters

People with ALS may view acetyl-L-carnitine as a possible supplement to discuss with their clinician, but this review does not establish that it slows the disease. ALS Untangled described the supplements as generally well tolerated, safe and inexpensive, while noting that the evidence remains limited.

Limitations and context

This is an independent expert review, not a new clinical trial. The review refers to preclinical evidence and only one clinical trial, and says further data are needed. Its statement that acetyl-L-carnitine may be theoretically promising should not be taken as proof of treatment benefit.

Summarised by Compass 10 August 2026

This summary was generated by AI from the source listed above. It is not medical advice, so read the original source for anything that affects your care.

Relevant to you?